A Safety and Efficacy Study of Brimonidine Intravitreal Implant in Geographic Atrophy Secondary to Age-related Macular Degeneration

PHASE2TerminatedINTERVENTIONAL
Enrollment

310

Participants

Timeline

Start Date

May 9, 2014

Primary Completion Date

March 30, 2018

Study Completion Date

March 30, 2018

Conditions
Geographic AtrophyMacular Degeneration
Interventions
DRUG

400 µg Brimonidine Implant

400 µg brimonidine implant in the study eye using Brimo DDS® applicator on Day 1, and every 3 months through Month 21.

OTHER

Sham

Sham treatment with needleless applicator (no implant) to the study eye on Day 1, and every 3 months through Month 21.

Trial Locations (41)

3002

Center for Eye Research Australia, Melbourne

6009

Lions Eye Institute, University of Western Australia, Nedlands

10122

Universita degli Studi di Torino, Torino

14620

Retina Associates of Western New York, Rochester

19107

Mid Atlantic Retina, Wills Eye Retina Surgeons, Philadelphia

20122

Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Milan

20132

IRCCS Ospedale San Raffaele, Milan

20157

"Dir IV Clinica Oculistica di Milano, Ospedale Generale Luigi Sacco ", Milan

28210

Charlotte Eye Ear Nose & Throat Associates, PA, Charlotte

30030

Georgia Retina, Decatur

32308

Southern Vitreoretinal Associates, PL, Tallahassee

32503

Retina Specialty Institute, Pensacola

33076

Service d'Ophtalmologie, Bordeaux

33711

Retina Vitreous Associates of Florida, St. Petersburg

33880

Center for Retina and Macular Disease, Winter Haven

33912

"National Ophthalmic Research Institute Retina Consultants of Southwest Florida", Fort Myers

35128

Universita degli Studi di Padova, Dipartimento di Neuroscienze, Padua

40138

Università di Cagliari (presidio San Giovanni di Dio), Bologna

46290

Raj K. Maturi, MD, Indianapolis

53127

"Universitat Bonn, Abteilung fur Augenheilkunde ", Bonn

72076

STZ Eyetrial, Tübingen

75231

Retina Foundation of the Southwest, Dallas

76012

Texas Retina Associates, Arlington

76087

Strategic Clinical Research Group, LLC, Willow Park

78503

Valley Retina Institute, McAllen

78705

"Austin Retina Associates ", Austin

79606

Retina Research Institute of Texas, Abilene

80909

Retina Consultants of Southern Colorado, PC, Colorado Springs

85014

Retinal Consultants of Arizona, Ltd., Retinal Research Institute, Phoenix

85020

Associated Retina Consultants, Phoenix

92037

University of California, San Diego, Jacobs Retina Center, Shiley Eye Center, La Jolla

94000

"Centre Hospitalier Intercommunal de Creteil ", Créteil

94040

Northern California Retina Vitreous Associates, Mountain View

97239

Casey Eye Institute, Oregon Health and Science University, Portland

97401

Oregon Retina, LLP, Eugene

09124

Università di Cagliari (presidio San Giovanni di Dio), Cagliari

BS1 2LX

Clinical Research Unit, Level2, Bristol Eye Hospital, Lower Maudlin Street, Bristol

GU16 7UJ

Frimley Park Hospital, Eye clinical trials Unit, Department of Opthalmology, Camberley

EC1V 2PD

Moorfields Eye Hospital, London

CV22 5PX

Macular Unit, Hospital of St Cross, Rugby

S10 2JF

Royal Hallamshire Hospital, Eye Department, Sheffield

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Allergan

INDUSTRY